A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DS / Durie-Salmon

[Related PubMed/MEDLINE]
Total Number of Papers: 26
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DS  (>> Co-occurring Abbreviation)
Long Form:   Durie-Salmon
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2018 Predictive value of 18 F-FDG PET/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma. 18 F-FDG, FLs, ISS, MM, NSS
2017 Analysis of clinical characteristics and prognostic factors of multiple myeloma: a retrospective single-center study of 787 cases. Hb, ISS, MM
2017 Multiple myeloma in Niger Delta, Nigeria: complications and the outcome of palliative interventions. ASCT, BPs, MM, MP
2017 Prognostic value of the bone turnover markers in multiple myeloma. BALP, MM, Riga, Latvia
2016 Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma. beta 2m, FLC-r, HLC, i-HLC, Ig, ISS, LDH, MM
2016 [Analysis of serum free light chains kappa/lamda ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System]. ISS, MM, mSMART, R-ISS
2015 [The value of chest computerized tomography in evaluation of bone disease and clinical prognosis of multiple myeloma]. CT, FISH, ISS, MM
2015 [Values of Detecting the Levels of beta2-MG, TNF-alpha, CRP, IL-6 in the Patients with Multiple Myeloma]. ---
2012 Chemotherapeutic agents increase the risk for pulmonary function test abnormalities in patients with multiple myeloma. BMI, MM, PFT
10  2012 International Staging System predicts prognosis of Chinese patients with multiple myeloma across different calendar periods with application of novel agents. ISS, MM
11  2012 [Expression of miR-21 in multiple myeloma and its clinical significance]. beta2-MG, BMMNC, miR-21, MM
12  2011 Analysis of the serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and different stages of multiple myeloma. MGUS, MM
13  2011 [Contribution of whole-body magnetic resonance in the diagnostics of monoclonal gammopathy of undetermined significance, multiple myeloma, and the assessment of Durie-Salmon Plus staging system]. D-S Plus, ISS, MGUS, MM, SP, WB-MRI
14  2011 [Expression and significance of B cell-activating factor of TNF family (BAFF) and B cell lymphoma/leukemia-2 (BCL-2) in multiple myeloma]. BAFF, Bcl-2, BMMNC, MM, MNC
15  2011 [Maintenance therapies of thalidomine and interferon-alpha in multiple myeloma]. IgA, IgG, ISS, MM, OS, PFS, PR
16  2010 Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. ISS, MM, OS
17  2010 [Clinical study of multiple myeloma: a report of 182 cases]. 2-MG, CRP, ISS, MM, ORR, OS, PFS
18  2010 [Contribution to the evaluation of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and in individual clinical stages of multiple myeloma]. beta 2m, ES, IMWG, ISS, MGUS, MM
19  2009 The relationship between some soluble osteogenic markers, angiogenic cytokines/other biological parameters and the stages of multiple myeloma evaluated according to the Durie-Salmon and International Prognostic Index stratification systems. IPI
20  2008 [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients]. beta2-MG, BMI, IFM, ISS, LDN, MM, OS, PS, TTP
21  2007 Clinical value of new staging systems for multiple myeloma. ISS, SWOG
22  2006 International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy. IPI, MM, OS, OSS
23  2006 New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy. APBSCT, ISS, MM, OS, PFS, SWOG
24  2003 Early versus deferred treatment for early stage multiple myeloma. ASCO, ASH, EHA, MM, RCT
25  2001 Multiple myeloma in elderly patients: presenting features and outcome. MM
26  1986 Prognostic factors and staging in multiple myeloma: a reappraisal. MM, MRC, MSS, MWJ, S beta 2M